{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:21:45Z","timestamp":1793733705270,"version":"4.6.1"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":569,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Pliant Therapeutics"},{"name":"Pliant Therapeutics"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Idiopathic pulmonary fibrosis (IPF) is a rare and progressive disease that causes progressive cough, exertional dyspnea, impaired quality of life, and death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Bexotegrast (PLN-74809) is an oral, once-daily, investigational drug in development for the treatment of IPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This Phase-2a multicenter, clinical trial randomized participants with IPF to receive, orally and once daily, bexotegrast at 40\u2009mg, 80\u2009mg, 160\u2009mg, or 320\u2009mg, or placebo, with or without background IPF therapy (pirfenidone or nintedanib), in an approximately 3:1 ratio in each bexotegrast dose cohort, for at least 12\u2009weeks. The primary endpoint was incidence of treatment-emergent adverse events (TEAEs). Exploratory efficacy endpoints included change from baseline in FVC, quantitative lung fibrosis (QLF) extent (%), and changes from baseline in fibrosis-related biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Bexotegrast was well tolerated, with similar rates of TEAEs in the pooled bexotegrast and placebo groups (62\/89 [69.7%] and 21\/31 [67.7%], respectively). Diarrhea was the most common TEAE; most participants with diarrhea also received nintedanib. Participants who were treated with bexotegrast experienced a reduction in FVC decline over 12\u2009weeks compared with those who received placebo, with or without background therapy. A dose-dependent antifibrotic effect of bexotegrast was observed with QLF imaging, and a decrease in fibrosis-associated biomarkers was observed with bexotegrast versus placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Bexotegrast demonstrated a favorable safety and tolerability profile, up to 12 weeks for the doses studied. Exploratory analyses suggest an antifibrotic effect according to FVC, QLF imaging, and circulating levels of fibrosis biomarkers.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT04396756).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202403-0636oc","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T13:03:15Z","timestamp":1717678995000},"page":"424-434","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":86,"title":["Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial"],"prefix":"10.1093","volume":"210","author":[{"given":"Lisa","family":"Lancaster","sequence":"first","affiliation":[{"name":"Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[{"name":"National Reference Centre for Rare Pulmonary Diseases (Orphalung), Louis Pradel Hospital, ERN-LUNG, Lyon, France"},{"name":"Claude Bernard University Lyon 1, UMR754, INRAE, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Ramaswamy","sequence":"additional","affiliation":[{"name":"PulmonIx, LLC, at Cone Health, Greensboro, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim A.","family":"Wuyts","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Unit for Interstitial Lung Diseases, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Gisli","family":"Jenkins","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Scholand","sequence":"additional","affiliation":[{"name":"Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah Health, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[{"name":"Pneumology Department, Mainz Lung Center, Mainz University Medical Center and Marienhaus Clinic Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Valenzuela","sequence":"additional","affiliation":[{"name":"ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, Autonoma de Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Ryerson","sequence":"additional","affiliation":[{"name":"Department of Medicine and Centre for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Goldin","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of California, Los Angeles, California"},{"name":"MedQIA LLC, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Hyun J.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of California, Los Angeles, California"},{"name":"MedQIA LLC, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzena","family":"Jurek","sequence":"additional","affiliation":[{"name":"Pliant Therapeutics, Inc., South San Francisco, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Decaris","sequence":"additional","affiliation":[{"name":"Pliant Therapeutics, Inc., South San Francisco, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Clark","sequence":"additional","affiliation":[{"name":"Pliant Therapeutics, Inc., South San Francisco, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Turner","sequence":"additional","affiliation":[{"name":"Pliant Therapeutics, Inc., South San Francisco, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris N.","family":"Barnes","sequence":"additional","affiliation":[{"name":"Pliant Therapeutics, Inc., South San Francisco, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardean E.","family":"Achneck","sequence":"additional","affiliation":[{"name":"Pliant Therapeutics, Inc., South San Francisco, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Cosgrove","sequence":"additional","affiliation":[{"name":"Pliant Therapeutics, Inc., South San Francisco, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric A.","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Pliant Therapeutics, Inc., South San Francisco, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Flaherty","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"2026022020471599500_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12931-021-01863-0","article-title":"Dual inhibition of \u03b1v\u03b26 and \u03b1v\u03b21 reduces fibrogenesis in lung tissue explants from patients with IPF","volume":"22","author":"Decaris","year":"2021","journal-title":"Respir Res"},{"key":"2026022020471599500_bib2","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026022020471599500_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12931-021-01791-z","article-title":"Global incidence and prevalence of idiopathic pulmonary fibrosis","volume":"22","author":"Maher","year":"2021","journal-title":"Respir Res"},{"key":"2026022020471599500_bib4","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1164\/rccm.201204-0754OC","article-title":"Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation","volume":"186","author":"Booth","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022020471599500_bib5","doi-asserted-by":"crossref","first-page":"1205948","DOI":"10.3389\/fphar.2023.1205948","article-title":"Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies","volume":"14","author":"Guo","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026022020471599500_bib6","doi-asserted-by":"crossref","first-page":"17534666231181537","DOI":"10.1177\/17534666231181537","article-title":"Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective","volume":"17","author":"Mai","year":"2023","journal-title":"Ther Adv Respir Dis"},{"key":"2026022020471599500_bib7","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022020471599500_bib8","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","article-title":"Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11","volume":"2","author":"Raghu","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026022020471599500_bib9","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s12325-018-0693-1","article-title":"Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK","volume":"35","author":"Strongman","year":"2018","journal-title":"Adv Ther"},{"key":"2026022020471599500_bib10","doi-asserted-by":"crossref","first-page":"e000397","DOI":"10.1136\/bmjresp-2018-000397","article-title":"Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials","volume":"6","author":"Lancaster","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"2026022020471599500_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026022020471599500_bib12","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"2026022020471599500_bib13","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"2026022020471599500_bib14","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"2026022020471599500_bib15","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","article-title":"Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"160","author":"Petnak","year":"2021","journal-title":"Chest"},{"key":"2026022020471599500_bib16","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N Engl J Med"},{"key":"2026022020471599500_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(\u00ae) trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir Med"},{"issue":"Suppl. 3b","key":"2026022020471599500_bib18","first-page":"S17","article-title":"Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis","volume":"23","author":"Fisher","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"2026022020471599500_bib19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000479976","article-title":"An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP)","volume":"94","author":"Costabel","year":"2017","journal-title":"Respiration"},{"key":"2026022020471599500_bib20","doi-asserted-by":"crossref","first-page":"00084-02018","DOI":"10.1183\/23120541.00084-2018","article-title":"Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study","volume":"4","author":"Cottin","year":"2018","journal-title":"ERJ Open Res"},{"key":"2026022020471599500_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S2213-2600(18)30339-4","article-title":"Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON","volume":"7","author":"Crestani","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026022020471599500_bib22","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1038\/s41467-020-18397-6","article-title":"Translational pharmacology of an inhaled small molecule \u03b1v\u03b26 integrin inhibitor for idiopathic pulmonary fibrosis","volume":"11","author":"John","year":"2020","journal-title":"Nat Commun"},{"key":"2026022020471599500_bib23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1183\/09031936.00210414","article-title":"\u03b1v\u03b26 integrin may be a potential prognostic biomarker in interstitial lung disease","volume":"46","author":"Saini","year":"2015","journal-title":"Eur Respir J"},{"key":"2026022020471599500_bib24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(21)00503-8","article-title":"Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis","volume":"10","author":"Bowman","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026022020471599500_bib25","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1164\/rccm.202301-0117OC","article-title":"Proteomic determinants of idiopathic pulmonary fibrosis survival","volume":"209","author":"Oldham","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022020471599500_bib26","first-page":"OA1423","article-title":"Late breaking abstract\u2014Safety, tolerability and antifibrotic activity of bexotegrast: phase 2a. INTEGRIS-IPF study (NCT04396756)","volume":"62","author":"Wuyts","year":"2023","journal-title":"Eur Respir J"},{"key":"2026022020471599500_bib27","first-page":"A2777","article-title":"PLN-74809 shows favorable safety and tolerability and indicates antifibrotic activity in a phase 2a study for the treatment of idiopathic pulmonary fibrosis","volume":"207","author":"Lancaster","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022020471599500_bib28","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"5 Suppl. 62","key":"2026022020471599500_bib29","first-page":"S26","article-title":"A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients","volume":"28","author":"Kim","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2026022020471599500_bib30","first-page":"A2437","article-title":"PLN-74809, a dual-selective inhibitor of \u03b1v\u03b26 and \u03b1v\u03b21, is well tolerated in over 280 healthy participants","volume":"205","author":"Cosgrove","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022020471599500_bib31","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1164\/rccm.202112-2824OC","article-title":"A phase IIb randomized study of an anti-\u03b1v\u03b26 monoclonal antibody in idiopathic pulmonary fibrosis","volume":"206","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022020471599500_bib32","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1164\/rccm.202205-0868LE","article-title":"Randomized phase IIa clinical study of an anti-\u03b1v\u03b26 monoclonal antibody in idiopathic pulmonary fibrosis","volume":"206","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022020471599500_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/toxsci\/kfaa024","article-title":"A potent pan-TGF\u03b2 neutralizing monoclonal antibody elicits cardiovascular toxicity in mice and cynomolgus monkeys","volume":"175","author":"Mitra","year":"2020","journal-title":"Toxicol Sci"},{"key":"2026022020471599500_bib34","first-page":"A5254","article-title":"PLN-74809, a dual-selective inhibitor of integrins \u03b1v\u03b26 and \u03b1v\u03b21, shows dose-dependent target engagement in the lungs of patients with idiopathic pulmonary fibrosis (IPF)","volume":"205","author":"Mooney","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022020471599500_bib35","first-page":"A5251","article-title":"PLN-74809, an oral, dual-selective \u03b1v\u03b26\/\u03b1v\u03b21 inhibitor in phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF), sustainably reduces transforming growth factor-beta (TGF-\u03b2) activity in the lungs of healthy participants with once-daily dosing","volume":"205","author":"Cosgrove","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022020471599500_bib36","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1513\/AnnalsATS.201606-458OC","article-title":"Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis","volume":"14","author":"Paterniti","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2026022020471599500_bib37","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1164\/rccm.202109-2091OC","article-title":"Three-month FVC change: a trial endpoint for idiopathic pulmonary fibrosis based on individual participant data meta-analysis","volume":"205","author":"Khan","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022020471599500_bib38","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1001\/jama.2023.5355","article-title":"Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials","volume":"329","author":"Maher","year":"2023","journal-title":"JAMA"},{"key":"2026022020471599500_bib39","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2213-2600(18)30181-4","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial","volume":"6","author":"Maher","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026022020471599500_bib40","doi-asserted-by":"crossref","first-page":"2201794","DOI":"10.1183\/13993003.01794-2022","article-title":"GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial","volume":"61","author":"Strambu","year":"2023","journal-title":"Eur Respir J"},{"key":"2026022020471599500_bib41","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","article-title":"Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"N Engl J Med"},{"key":"2026022020471599500_bib42","doi-asserted-by":"crossref","first-page":"1902151","DOI":"10.1183\/13993003.02151-2019","article-title":"FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change","volume":"55","author":"Nathan","year":"2020","journal-title":"Eur Respir J"},{"key":"2026022020471599500_bib43","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1007\/s12325-019-01093-3","article-title":"Modelling forced vital capacity in idiopathic pulmonary fibrosis: optimising trial design","volume":"36","author":"Santermans","year":"2019","journal-title":"Adv Ther"},{"key":"2026022020471599500_bib44","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1183\/13993003.02204-2014","article-title":"Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough","volume":"46","author":"Thabut","year":"2015","journal-title":"Eur Respir J"},{"key":"2026022020471599500_bib45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12931-023-02503-5","article-title":"Lung function trajectories in patients with idiopathic pulmonary fibrosis","volume":"24","author":"Neely","year":"2023","journal-title":"Respir Res"},{"key":"2026022020471599500_bib46","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.acra.2014.08.004","article-title":"Comparison of the quantitative CT imaging biomarkers of idiopathic pulmonary fibrosis at baseline and early change with an interval of 7 months","volume":"22","author":"Kim","year":"2015","journal-title":"Acad Radiol"},{"key":"2026022020471599500_bib47","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1164\/rccm.201709-1845OC","article-title":"Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"197","author":"Kafaja","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022020471599500_bib48","doi-asserted-by":"crossref","first-page":"17534666211004238","DOI":"10.1177\/17534666211004238","article-title":"The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis","volume":"15","author":"Kim","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"2026022020471599500_bib49","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s00330-019-06402-6","article-title":"Prediction of idiopathic pulmonary fibrosis progression using early quantitative changes on CT imaging for a short term of clinical 18-24-month follow-ups","volume":"30","author":"Kim","year":"2020","journal-title":"Eur Radiol"},{"key":"2026022020471599500_bib50","doi-asserted-by":"crossref","first-page":"17409","DOI":"10.1016\/S0021-9258(18)41941-2","article-title":"Transforming growth factor beta differentially regulates expression of integrin subunits in guinea pig airway epithelial cells","volume":"267","author":"Sheppard","year":"1992","journal-title":"J Biol Chem"},{"key":"2026022020471599500_bib51","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12931-019-1118-7","article-title":"Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort","volume":"20","author":"Organ","year":"2019","journal-title":"Respir Res"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/210\/4\/424\/66997797\/ajrccm_210_4_424.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/210\/4\/424\/66997797\/ajrccm_210_4_424.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T01:47:28Z","timestamp":1771638448000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/210\/4\/424\/8491434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8,15]]},"published-print":{"date-parts":[[2024,8,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202403-0636oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"2024-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}